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The effects of cholecystokinin receptor antagonist, di- 
pentyl-3,4-dichloroproglumide (DDP), on stimulated 
pancreatic and gastric secretion were studied in the rat. 
DDP dose-dependently inhibited cholecystokinin-stim- 
ulated amylase release from dispersed acinar cells. In 
uiuo, DDP inhibited cholecystokinin octapeptide-stim- 
ulated amylase and protein secretion. DDP also inhibited 
pentagastrin-stimulated gastric acid secretion in vivo. 
Meal-stimulated acid output was decreased by 34% (DDP 
400 pg/kg/hr) but responsiveness to histamine or para- 
chlorophenyl-y-aminobutyric acid was unchanged. 
Q 1999 Academic Press, Inc. 
INTRODUCTION 
A number of compounds have been developed recently 
with activities as receptor antagonists for peptide hor- 
mones of the gastrointestinal tract. These compounds 
have exciting potential as probes for elucidation of control 
mechanisms of gastrointestinal function and for inves- 
tigation of the role of gastrointestinal hormones in various 
disease states. Future therapeutic uses of specific receptor 
antagonists is an important prospect. 
Among the amino acid derivatives, a series of glutaramic 
acid congeners have recently been reported which are po- 
tent antagonists of the pancreatic stimulatory actions of 
CCK in vitro [ll]. Several of the agents demonstrate 
greatly improved in vitro potency when compared to ben- 
zotript or proglumide. Glutaramic acid derivatives have 
been reported to inhibit binding of CCK to guinea pig 
gallbladder and to rat pancreatic tissues and brain [12, 
131. Glutaramic acid derivatives have been reported by 
Niederau et al. to competitively inhibit the binding of 
CCK to dispersed rat acinar cells and to dose-dependently 
inhibit amylase release from dispersed cells [13]. The 
current study was designed to correlate in vitro and in 
uiuo activities of one of the most potent of these com- 
pounds, dipentyl-3,4dichloroproglumide, on CCK-stim- 
ulated pancreatic secretion. In addition, because of the 
close structural similarities between the active sites of 
the CCK and gastrin molecules, the specificity of this 
receptor antagonist for in uiuo experimentation was as- 
sessed by examining its effects on stimulated gastric acid 
secretion. 
MATERIALS AND METHODS 
Substances 
A number of compounds have been described which DL - 4 - (3,4 - Dimethylbenzoylamino) - 5 - (di - n - pentyl- 
demonstrate cholecystokinin (CCK) receptor antagonism amino)-5oxopentanoic acid (dipentyl-3,4dichloropro- 
in vitro. Four general classes of CCK receptor antagonists glumide-referred to subsequently in this text as DDP) 
have been recognized: (1) derivatives of cyclic nucleotides was a generous gift of Dr. I. Setnikar, Rotta Laboratorium, 
such as dibutyryl cyclic GMP; (2) fragments or analogs Milan, Italy. For in uiuo experiments, DDP was admin- 
of the C-terminal region of CCK; (3) nonpeptide com- istered after it was dissolved in 0.9% NaCl. Cholecysto- 
pounds such as asperlicin, derived from Apergillus aUi- kinin octapeptide (CCK8; Peninsula Labs, Belmont, CA), 
aceus; and (4) amino acid derivatives such as benzotript and pentagastrin (Ayerst Laboratories) were prepared as 
or proglumide [l-8]. While the various agents have been solutions in 0.1% bovine serum albumin (Sigma Chemical 
useful for investigation of pancreatic function in vitro, Co., St. Louis, MO). Histamine (Eli Lilly, Indianapolis, 
most of these compounds have pharmacologic deficits IN), and para-chlorophenyl-y-aminobutyric acid (PCP- 
which limit their use for in uiuo experimentation or for GABA, Geigy Pharmaceuticals, Summit, NJ) were dis- 
therapy. For example, both benzotript and dibutyryl cyclic solved in 0.9% NaCl. Liquid peptone meals (Bactopep- 
GMP are toxic at doses which achieve significant inhib- tone; Difco Laboratories, Detroit, MI) were prepared at 
itory actions in uiuo [9]. CCK analogs and C-terminal 5% (w/v) concentrations; the osmolarity and pH of each 
peptide fragments require intravenous infusion and are meal were adjusted to 320 mOsm and 5.5 by addition of 
rapidly degraded in serum or blood [lo]. Benzotript and NaCl and 4 N HCl, respectively. All other chemicals and 
proglumide are limited by unacceptably low potencies. supplies were purchased from Sigma. 
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FIG. 1. Effect of DDP on CCK-stimulated amylase release from 
dispersed rat acinar cells. Acinar cells were stimulated with increasing 
doses of CCK8 in the presence of lOme, 5 X 10-s, and lo-’ M DDP. 
Results are calculated as percentages of total amylase after subtraction 
of basal release. Each value was determined in duplicate. The curves 
represent mean values from six separate experiments. Standard errors 
were less than 10% in all instances. 
Isolated Pancreatic Acini 
The method for preparation of isolated rat pancreatic 
acini is a modification of the methods of Amsterdam et 
al. [ 141 and Williams et al. [15]. Male Sprague-Dawley 
rats, weighing 200-250 g, were fasted for 16 hr before 
sacrifice. The pancreas was removed and carefully dis- 
sected free of nonpancreatic tissue. With a 25-gauge nee- 
dle, the pancreas was injected with 5 ml of highly purified 
collagenase solution [Krebs-Ringer-Hepes buffer plus 0.1 
mg/ml soybean trypsin inhibitor (Sigma), 0.1 n&f Ca2+, 
11.1 mM glucose, and 0.1 mg/ml highly purified collage- 
nase (Worthington Biochemicals)]. Pancreatic tissue was 
incubated for three periods of 15 to 30 min with colla- 
genase solution at 37°C. The tissue was dissociated by 
forceful aspiration through three Pasteur pipets of de- 
creasing size. Debris was removed by passage through Ni- 
tex gauge (200 pm). Isolated acini were centrifuged in 4% 
albumin and then resuspended in buffer. For dose-re- 
sponse studies, the acini were incubated with various 
concentrations of secretogogue and antagonists for 20 min 
at 37°C in a shaking water bath. Amylase release into the 
supernatant was assayed spectrophotometrically by a 
modification of the method described by Bernfeld [ 161. 
Amylase release was expressed as the percentage of total 
amylase present. 
A Schild plot for inhibition of amylase release by DDP 
was calculated from CCK dose-response curves in the 
presence of increasing amounts of the inhibitor [ 171. For 
each shift in the dose-response curves, the ratios of the 
50% inhibitory dose of CCK (ID& in the presence of 
DDP to CCK alone were calculated. The negative log of 
the molar doses of DDP were plotted against the respec- 
tive IDso values. The least-squares method was used to 
find the regression line. 
In Vivo Pancreatic Secretory Studies 
In vivo effects of DDP on pancreatic exocrine secretion 
were examined in urethane-anesthetized animals. The 
National Research Council’s Guide for Care and Use of 
Laboratory Animals was followed. After a 16-hr fast, rats 
were injected intraperitoneally with urethane (1.25 g/kg). 
The pancreas was exposed through a short midline inci- 
sion. A small incision was made in the pancreatic duct 
just proximal to the duodenal wall; the duct was cannu- 
lated with polyethylene tubing. Bile-pancreatic juice was 
collected by gravity drainage in 30-min samples. Through 
a separate duodenal puncture site, a small polyethylene 
catheter was inserted for infusion of bile pancreatic juice 
at the rate of 1.5 cc/hr. The infused bile-pancreatic juice 
had been previously collected from normal rats. A 23- 
gauge needle was placed in the femoral vein for infusion 
of test substances; for those experiments in which more 
than one peptide or test substance was infused, bilateral 
femoral catheters were used. 
Pancreatic secretory volume was recorded and samples 
of pancreatic secretion were assayed for protein and am- 
ylase. Protein content was determined by the method of 
Lowry et al. [ 181. 
In viva Ch.stric Secretory &u&es 
The effects of DDP on in vivo gastric acid secretion 
were studied using an acute gastric fistula preparation. 
After a 16-hr fast, rats were anesthetized with intraperi- 
toneal urethane. The trachea was cannulated and the 
esophagus was ligated in the neck. Vagal nerve trunks 
were carefully preserved during esophageal ligation. 
Through a small midline incision, the stomach was ex- 
posed and a double-lumen gastric cannula was inserted 
via the forestomach. The pylorus was ligated. Venous ac- 
cess was achieved with femoral vein catheters. For studies 
that included intravenous or subcutaneous administration 
of test substances, the gastric lumen was rinsed with 20 
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FIG. 2. Schild plot for inhibition of CCK-stimulated amylase release 
with increasing concentrations of DDP. Slope equals 0.93. The intercept 
with the horizontal axis, Ki, is 3 X 10-r M. 
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FIG. 3. Effects of DDP on CCK-stimulated pancreatic output of protein (A) and amylase (B). Pancreatic secretion was collected in 30-min 
samples. DDP was infused intravenously at doses of 0, 25, 50, and 200 pg/kg/hr starting 30 min before stepwise, increasing doses of CCK8. The 
curves represent mean values from groups of six animals each. 
cc of saline every 10 min. Acid production was measured 
by titration of the gastric rinse solution with 0.1 N NaOH 
to neutrality. For liquid meal studies, the meal was in- 
stilled at a volume of 10 ml. After 10 min, the test meal 
was evacuated, and the stomach was rinsed with 20 cc of 
saline. Acid production was measured for the liquid meal 
stimulus by titration to pH 5.5. Acid secretion was ex- 
pressed as milliequivalents per 10 min. 
Statistical Analysis 
Data from in viva experiments were calculated as group 
means f SEM and were analyzed using a one-way analysis 
of variance. Significance was assumed for P values less 
than 0.05. 
RESULTS 
Effects on in Vitro Amylase Release 
Increasing concentrations of CCK8 dose-dependently 
stimulated amylase release from dispersed rat acinar cells. 
Amylase release was maximal at 10-l’ M, with decreased 
responses at higher concentrations (Fig. 1). The CCK 
dose-response curve was shifted to the right in the pres- 
ence of the CCK antagonist, DDP. The magnitude of the 
shift was related to the concentration of the antagonist. 
However, maximal amylase release, expressed as per- 
centage of total amylase, was unaffected by increasing 
concentrations of DDP. 
Analysis of the data by a Schild plot demonstrates that 
DDP acts as a competitive antagonist of CCK stimulation 
of amylase secretion (Fig. 2). The Ki, determined from 
the intercept with the horizontal axis, was 3 X 10V7 M. 
The slope of the line was 0.93. 
Effects on in Vivo Pancreatic Secretion 
Increasing concentrations of CCKS, administered in- 
travenously, dose-dependently increased pancreatic am- 
ylase output. Maximum amylase secretion was observed 
at a CCK dose of 1.1 hg/kg/hr, the highest dose employed. 
DDP administered intravenously for 30 min prior to CCK 
infusion did not alter basal protein or amylase output 
(Fig. 3). However, the antagonist (at doses of 50 and 200 
pg/kg/hr) caused significant inhibition of pancreatic am- 
ylase and total protein responses to CCK stimulation. 
The maximal pancreatic exocrine response to CCK stim- 
ulation was significantly decreased for all doses of DDP 
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FIG. 4. Effect of DDP on pentagastrin-stimulated gastric acid out- 
put. Gastric secretion is expressed as group means for 30-min collections. 
Each experimental group contained six animals. DDP was infused in- 
travenously at doses of 0, 50,100, and 400 pg/kg/hr, beginning 30 min 
before increasing doses of pentagastrin. 
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FIG. 6. Effect of DDP on gastric acid output in response to his- 
tamine or PCP-GABA. DDP at a dose of 400 pg/kg/hr was infused 
intravenously starting 30 min prior to administration of histamine (10 
mg/kg subcutaneously) or PCP-GABA (4 mg/kg subcutaneously). 
Effects on in Viuo Gastric Acid Secretion 
Increasing concentrations of pentagastrin, ranging from 
1 to 64 pg/kg/hr caused dose-dependent increases in gas- 
tric acid output (Fig. 4). Decreases in pentagastrin-stim- 
ulated acid secretion were noted in association with DDP 
administration (Fig. 5). These differences achieved sta- 
tistical significance at a dose of 400 pg/kg/hr. At this 
dose, DDP nearly abolished the gastric acid response to 
all doses of pentagastrin tested. 
The in uiuo specificity of DDP was demonstrated by 
the absence of significant effect on acid secretion stim- 
ulated by histamine or by the vagal stimulatory agent 
PCP-GABA (Fig. 5). However, DDP reduced 30-min peak 
acid output in response to a 5% liver meal by approxi- 
mately 34% (Fig. 6). 
DISCUSSION 
Cholecystokinin is an important regulatory peptide 
and peripheral nervous systems [ 191. The biological ac- 
tions of CCK include regulation of pancreatic secretion 
and gallbladder contraction and modulation of gastroin- 
testinal motility. Physiologic roles for CCK have been 
proposed for activities as diverse as neurotransmission 
and control of satiety. The availability of potent and spe- 
cific CCK receptor antagonists for in vitro studies has 
helped define the role of CCK in a number of physiologic 
and pathologic states. However, while effective in uitro, 
most CCK receptor antagonists developed initially were 
not useful for in uiuo investigations nor as potential ther- 
apeutic agents. Derivatives of cyclic nucleotides such as 
dibutyryl cGMP are potent inhibitors of CCK-stimulated 
amylase release in vitro but have significant toxicity in 
living animals [2]. Partial amino acid sequences of the 
biologically active C terminus of CCK, for example, 
CCK(27-32)-NH2 and acetyl CCK(26-32)-NHP, also ex- 
hibit potent inhibition of CCK actions in vitro [3]. How- 
ever, rapid enzymatic degradation of such peptide seg- 
ments in serum precludes successful use in most living 
animal models [lo]. 
Among amino acid congener CCK receptor antagonists, 
proglumide and benzotript are the best characterized and 
have been used to treat human subjects with peptic ulcer 
disease [ 201. Both drugs have excellent clinical safety rec- 
ords, but low potency has limited their usefulness. DDP, 
which like proglumide and benzotript is a derivative of 
glutaramic acid, has a greatly increased inhibitory potency 
in uitro for CCK stimulation of pancreatic tissues. Nie- 
derau and co-workers have recently reported that the an- 
tagonist is 2500-4000 times more potent than proglumide 
in the inhibition of CCK%stimulated amylase release 
from dispersed rat acinar cells [13]. DDP demonstrated 
a similar increase in potency for inhibition of binding of 
‘251-CCK to rat pancreatic acini. The compound displayed 
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FIG. 6. Effects of DDP (400 pg/kg/hr) on gastric acid secretion in 
~- with a wide distribution in the gut as well as the central response to 5% peptone meal. 
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The current study confirms the ability of DDP to com- 
petitively inhibit CCK-stimulated amylase release from 
dispersed rat acinar cells. Increasing concentrations of 
the antagonist caused progressive shift of CCK dose-re- 
sponse curves to the right without altering maximal re- 
sponses. Analysis of the data by the method of Schild 
yielded a Ki value of 3 X lo-’ M. In addition, the study 
demonstrated that DDP effectively inhibited CCK-stim- 
ulated pancreatic exocrine secretion in vivo. Amylase se- 
cretion in vivo was dose-dependently inhibited by DDP; 
the degree of inhibition was significant for all doses of 
CCK when DDP was administered intravenously at a dose 
of 200 pg/kg/hr. 
Because of the structural homology of the biologically 
active C-terminal regions of CCK and gastrin, it is not 
surprising that DDP also demonstrated inhibitory activity 
against pentagastrin-stimulated gastric acid secretion. 
Nearly total inhibition of acid secretion was observed at 
a dose of 400 pg/kg/hr. This finding suggests that in vivo 
experiments that employ high-dose DDP blockade to 
demonstrate CCK-specific actions must be interpreted 
with caution. DDP did not affect acid responses to his- 
tamine or PCP-GABA [22]. In contrast, DDP inhibited 
gastric acid responses to a liver extract meal by approx- 
imately 34%. The inhibition-of-meal response was similar 
to that reported in rats by Goto and co-workers using a 
monoclonal antibody to gastrin [23]. 
In conclusion, dipentyl-3,4dichloroproglumide is a po- 
tent inhibitor of CCK-stimulated pancreatic exocrine 
function, effective both in vitro and in vivo. However, the 
agent also demonstrated significant in vivo inhibition of 
pentagastrin-stimulated gastric acid secretion when 
higher doses were used. The antagonist may serve as a 
useful probe for the investigation of pancreatic and gastric 
pathophysiology. In the future, the agent may have po- 
tential as a therapeutic agent for selected pancreatic dis- 
ease, an exciting and important prospect. 
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